HRMY

28.75

2.64% -0.78

Handel nachbörslich: 28.75

Harmony Biosciences Holdings Inc (HRMY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HRMY? Forum Prognose

Schlusskurs vom Vortag:

$29.53

Offen:

$29.31

24-Stunden-Volumen:

919.71K

Relative Volume:

1.40

Marktkapitalisierung:

$1.65B

Einnahmen:

$681.88M

Nettoeinkommen (Verlust:

$122.63M

KGV:

13.63

EPS:

2.11

Netto-Cashflow:

$220.18M

1W Leistung:

+2.20%

1M Leistung:

-12.13%

6M Leistung:

-19.01%

1J Leistung:

-2.61%

1-Tages-Spanne:

$27.71

$29.59

1-Wochen-Bereich:

$26.47

$29.67

52-Wochen-Spanne:

$26.47

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Firmenname

Harmony Biosciences Holdings Inc

Sektor

Healthcare (1159)

Branche

Biotechnology (679)

Telefon

(484) 539-9800

Adresse

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Mitarbeiter

268

Twitter

Nächster Verdiensttermin

2024-10-29

Neueste SEC-Einreichungen

HRMY's Discussions on Twitter

Vergleichen Sie HRMY mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HRMY Harmony Biosciences Holdings Inc	28.75	1.65B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	500.49	128.67B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	557.91	60.99B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	605.38	36.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	230.93	29.89B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.84	25.73B	3.81B	-644.79M	-669.77M	-6.24

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-12-17	Eingeleitet	H.C. Wainwright	Buy
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-09-10	Eingeleitet	UBS	Buy
2024-06-21	Eingeleitet	Citigroup	Buy
2024-01-02	Herabstufung	BofA Securities	Neutral → Underperform
2023-09-25	Herabstufung	Goldman	Neutral → Sell
2023-09-07	Eingeleitet	Berenberg	Buy
2023-04-20	Eingeleitet	BofA Securities	Neutral
2022-10-14	Hochstufung	Janney	Neutral → Buy
2022-10-14	Hochstufung	Jefferies	Hold → Buy
2022-08-03	Herabstufung	Jefferies	Buy → Hold
2022-07-13	Herabstufung	Goldman	Buy → Neutral
2022-07-07	Eingeleitet	Mizuho	Buy
2022-04-14	Eingeleitet	Cantor Fitzgerald	Overweight
2021-12-01	Eingeleitet	Oppenheimer	Outperform
2021-11-04	Eingeleitet	Raymond James	Outperform
2021-09-23	Eingeleitet	Needham	Buy
2021-03-29	Hochstufung	Goldman	Neutral → Buy
2020-09-14	Eingeleitet	Goldman	Neutral
2020-09-14	Eingeleitet	Jefferies	Buy
2020-09-14	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten

Apr 14, 2025

Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome - MyChesCo

Apr 14, 2025

Apr 12, 2025

Harmony Biosciences Appoints Ron Philip to Board of Directors - MSN

Apr 12, 2025

Apr 10, 2025

Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from HC Wainwright - Defense World

Apr 10, 2025

Apr 08, 2025

Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views - Benzinga

Apr 08, 2025

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome - BioSpace

Apr 08, 2025

Oppenheimer maintains Harmony Biosciences Outperform rating By Investing.com - Investing.com UK

Apr 08, 2025

Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Apr 08, 2025

Oppenheimer on Harmony Biosciences (HRMY): 'we remain pleased with WAKIX's 4Q24 performance' - StreetInsider

Apr 08, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect - markets.businessinsider.com

Apr 08, 2025

Harmony Biosciences reports progress in Fragile X syndrome gel treatment - Investing.com

Apr 08, 2025

Breakthrough: New Fragile X Treatment Achieves 73% Success Rate in Long-term Study - Stock Titan

Apr 08, 2025

Apr 07, 2025

HRMY stock touches 52-week low at $27.87 amid market shifts By Investing.com - Investing.com South Africa

Apr 07, 2025

HRMY stock touches 52-week low at $27.87 amid market shifts - Investing.com

Apr 07, 2025

Corebridge Financial Inc. Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Apr 07, 2025

Vanguard Group Inc. Has $162.88 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - The AM Reporter

Apr 07, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Holdings Increased by Vanguard Group Inc. - Defense World

Apr 07, 2025

Arrowstreet Capital Limited Partnership Has $10.21 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - The AM Reporter

Apr 07, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Rating of “Buy” by Analysts - The AM Reporter

Apr 07, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Apr 07, 2025

Apr 06, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Apr 06, 2025

Apr 04, 2025